Company Description
Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease.
The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.
Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans.
The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022.
Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.
| Country | United States |
| Founded | 1983 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 116 |
| CEO | Johan M. Spoor |
Contact Details
Address: 2401 Elliott Avenue, Suite 320 Seattle, Washington 98121 United States | |
| Phone | (509) 375-1202 |
| Website | perspectivetherapeutics.com |
Stock Details
| Ticker Symbol | CATX |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000728387 |
| ISIN Number | US46489V1044 |
| Employer ID | 41-1458152 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Johan M. Spoor | Chief Executive Officer and Director |
| Jonathan R. Hunt | Chief Financial Officer and Co-Principal Financial Officer |
| Dr. Markus Puhlmann M.B.A., M.D. | Chief Medical Officer |
| Shane Cobb | Executive Vice President of Operations |
| Mark J. Austin CPA | Vice President of Finance, Corporate Controller, Co-Principal Financial, Principal Acc. Officer and Secretary |
| Dr. Michael K. Schultz Ph.D. | Chief Science Officer |
| Andrew Bright | Executive Vice President of Brachytherapy |
| Amos Hedt BA, PGradDip | Chief Business Strategy Officer |
| Dr. Frances L. Johnson M.D. | Chief Innovation Officer |
| David Hauser Ph.D. | Senior Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 18, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 16, 2024 | 8-K | Current Report |
| Apr 9, 2024 | EFFECT | Notice of Effectiveness |
| Apr 9, 2024 | 424B3 | Prospectus |
| Apr 8, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 8, 2024 | 8-K | Current Report |
| Apr 3, 2024 | 8-K | Current Report |
| Apr 1, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 29, 2024 | S-3 | Registration statement under Securities Act of 1933 |